Immunotherapy has been one of the most promising approaches in
tumor-treating fields, including
immune checkpoint inhibitors,
bispecific antibodies, and
CAR-T
therapy, etc. It has achieved major breakthroughs in the
treatment of hematological and other
malignancies. However, related
safety management issues are becoming increasingly prominent, especially the
diagnosis and
treatment of coagulopathy deserves the
attention of clinical and
laboratory physicians. Therefore, this
review summarizes
immunotherapy-related coagulopathy from the perspectives of
epidemiology, pathogenesis and
laboratory indicators and provides guidance for early clinical identification,
diagnosis and intervention.